Senza categoria Archives - Page 13 of 13 - Elixi International

4 March 2019

Waylivra (volanesorsen), first treatment for rare disease characterised by high levels of triglycerides in blood

4 March 2019

Palynziq (pegvaliase), new treatment for phenylketonuria, a rare inherited metabolic disease

4 March 2019

Zynquista (sotagliflozin), New add-on treatment to insulin for treatment of certain patients with type 1 diabetes

18 February 2019

The World Health Organisation issues an alert on falsified ICLUSIG traded globally

10 February 2019

Forxiga and Edistride (Dapagliflozin) recommended by EMA as first oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

7 February 2019

Cablivi (caplacizumab-yhdp) approved by FDA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

25 January 2019

First generic version of Sabril (vigabatrin) approved by FDA for the treatment of complex partial seizures

25 January 2019

Ultomiris (ravulizumab), approved by FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)

11 January 2019

European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients

7 January 2019

FDA approves Elzonris (tagraxofusp-erzs), first treatment for rare blood disease